News from neovii pharmaceuticals ag A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 24, 2017, 11:59 ET Neovii Announces Publication in Journal of Clinical Oncology Demonstrating Grafalon® Reduces Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation

Neovii Pharmaceuticals AG ("Neovii") today announced the publication in the Journal of Clinical Oncology1 of the results of a prospective,...


Sep 15, 2017, 08:54 ET Neovii Pharmaceuticals AG annonce l'arrivée d'un nouveau PDG

Alexandre Sudarskis, Président-directeur général (PDG) de Neovii Pharmaceuticals va quitter ses fonctions car il a atteint l'âge de la retraite....


Sep 15, 2017, 05:47 ET Neovii Pharmaceuticals AG anuncia a su nuevo consejero delegado

Alexandre Sudarskis, consejero delegado de Neovii Pharmaceuticals, dejará su cargo como consejero delegado al haber alcanzado su edad de jubilación....


Sep 15, 2017, 04:11 ET Neovii Pharmaceuticals AG Announces New CEO

Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii...


Jun 26, 2017, 07:45 ET Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy

The 8-year follow-up results of a randomized phase 3 multicenter trial in adult patients with hematologic malignancies clearly showed more favorable...


Jun 26, 2017, 04:34 ET Neovii: Los resultados a largo plazo apoyan el uso de Grafalon® como terapia estándar

- Neovii: Los resultados a largo plazo tras la profilaxis estándar de injerto frente a enfermedad huésped (GvHD) en transplante de célula...


Jan 19, 2016, 03:36 ET Estudio europeo en pacientes con leucemia aguda muestra la inclusión de Grafalon® antes del trasplante de células madre

- Estudio europeo en pacientes con leucemia aguda muestra la inclusión de Grafalon® (inmunoglobulina anti linfocitos T) en un régimen acondicionado...